E.U. Support Growing For TB Vaccine Development

In a guest post in the Global Health Technologies Coalition’s “Breakthroughs” blog, Kari Stoever, vice president of external affairs at Aeras, “writes about European support for new vaccines against tuberculosis (TB).” She notes, “Europe is a major contributor to the development of vaccines globally, with as much as 75 percent of the global TB vaccine portfolio either originating in Europe or being developed in partnership with European public or private organizations.” She highlights a recent “€25 million (approximately $34 million) call for proposals to accelerate the development of new TB vaccines” by the E.U., which she says “comes as an important new collaboration between European funders and a global network of researchers is forming” (12/17).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.